SECOS restructure to generate significant growth in bioplastic resin sales
Sustainable and eco-friendly bioplastics developer SECOS Group Limited (ASX:SES) has completed a strategic review into its wholly owned subsidiary Stellar Films Australia (SFA).
The review into the SFA division, which produces traditional plastic films, comes as the company executes its strategy to be a world leader in bioplastics.
In light of the review, SECOS has resolved to continue the transfer of SFA customers to its Malaysian operations and commence the orderly cessation of its Australian film manufacturing operations.
This decision to transfer SFA customers to its Malaysian operations is anticipated to achieve significant operating and overhead cost savings. Once the transition period has passed, SECOS expects to achieve an improvement to net profit after tax (NPAT) of more than $0.9 million per annum.
The review was undertaken by independent consultant Promentor, whose findings confirmed the Board’s expectation that SECOS can achieve significant operating and overhead cost savings by moving its current traditional plastic film production from its facility in Melbourne to its production facilities in Malaysia.
The decision will see SECOS incur a one-off cash charge of $0.9 million in FY19 which will be funded from the company’s recently completed share placement and rights issue. SECOS notes that the significant ongoing costs of keeping SFA open under its existing structure mean shareholders’ best interests will be served by taking this action immediately.
The review also determined that SECOS can improve profitability by ceasing to operate the SFA business, although the level of improvement will depend on how much business can be successfully transferred to the company’s Malaysian operations.
As such, at this stage the company will continue with its existing plans to transfer SFA customers to its Malaysian operations and will commence the orderly cessation of its Australian film manufacturing operations. It does expect most Australian customers to transfer their business to the company’s Malaysian operations.
SECOS has an established blue-chip traditional hygiene film customer base in its Malaysian operations with a unique opportunity to transition them to bioplastic (compostable and biohybrid) film sales.
SECOS Executive Chairman, Richard Tegoni, said, “The decision by the Board to cease operations in Australia is an important step to further lower SECOS Group’s cost base and to consolidate and optimise its manufacturing assets.
“With this improved structure, we expect to continue to deliver significant growth in bioplastic resin sales, and over time upgrade our world-class hygiene film production to support compostable and breathable film for the large and attractive feminine and infant hygiene markets.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.